Published in J Immunol on June 01, 1987
Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med (1991) 2.11
T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J Exp Med (1996) 1.17
Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically. Br J Cancer (1994) 1.15
An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc Natl Acad Sci U S A (1996) 1.02
In vivo stimulation and restoration of the immune response by the noninflammatory fragment 163-171 of human interleukin 1 beta. J Exp Med (1988) 0.93
Analysis of changes in the total lymphocyte and eosinophil count during immunotherapy for metastatic renal cell carcinoma: correlation with response and survival. J Korean Med Sci (2007) 0.84
Histologic and immunohistochemical characterization of tumor and inflammatory infiltrates in oral squamous cell carcinomas treated with local multikine immunotherapy: the macrophage at the front line. Eur Arch Otorhinolaryngol (2003) 0.78
A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell (1992) 6.86
Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice. EMBO J (1995) 3.48
Natural killer cells: characteristics and regulation of activity. Immunol Rev (1979) 3.14
The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood (2001) 2.92
The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells. Immunol Today (1994) 2.66
DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol (2000) 2.65
Tumor localization of radiolabeled antibodies against carcinoembryonic antigen in patients with carcinoma: a critical evaluation. N Engl J Med (1980) 2.50
Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase. J Exp Med (1994) 2.47
Constitutive activation of NF-kappaB and T-cell leukemia/lymphoma in Notch3 transgenic mice. EMBO J (2000) 2.41
The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells. J Immunol (1998) 2.32
Antitumor vaccination: where we stand. Haematologica (2000) 2.30
Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med (1998) 2.08
Six-minute walking performance in patients with moderate-to-severe heart failure; is it a useful indicator in clinical practice? Eur Heart J (2001) 2.07
Involvement of p21ras activation in T cell CD69 expression. Eur J Immunol (1994) 1.85
Human monocytes constitutively express membrane-bound, biologically active, and interferon-gamma-upregulated interleukin-15. Blood (1999) 1.71
Myocardial scarring by delayed enhancement cardiovascular magnetic resonance in thalassaemia major. Heart (2009) 1.71
Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med (2001) 1.66
Recent increase of breast cancer incidence among women under the age of forty. Br J Cancer (2007) 1.57
Triggering of human monocyte activation through CD69, a member of the natural killer cell gene complex family of signal transducing receptors. J Exp Med (1994) 1.55
Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver. EMBO J (1998) 1.50
Anaplastic large cell lymphomas: a study of 75 pediatric patients. Pediatr Dev Pathol (2007) 1.46
Establishment and characterization of a human neuroblastoma cell line. Int J Cancer (1989) 1.43
The viral chemokine macrophage inflammatory protein-II is a selective Th2 chemoattractant. Blood (1998) 1.42
Concomitant factors of decompensation in chronic heart failure. Am J Cardiol (1996) 1.42
Adjuvant propofol enables better control of nausea and emesis secondary to chemotherapy for breast cancer. Can J Anaesth (1994) 1.41
Family treatment of symptomatic children with Helicobacter pylori infection. Ital J Gastroenterol Hepatol (1997) 1.41
Vitamin D3: a transcriptional modulator of the interferon-gamma gene. Eur J Immunol (1998) 1.39
Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res (1992) 1.39
Interferon-gamma receptor 2 expression as the deciding factor in human T, B, and myeloid cell proliferation or death. J Leukoc Biol (2001) 1.39
Aluminum and dialysis arthropathy. Nephron (1990) 1.39
Tumor necrosis factor alters synaptic transmission in rat hippocampal slices. Neurosci Lett (1992) 1.38
Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. Lab Invest (1999) 1.37
Functional expression of Fas and Fas ligand on human gut lamina propria T lymphocytes. A potential role for the acidic sphingomyelinase pathway in normal immunoregulation. J Clin Invest (1996) 1.36
Group B streptococci persist inside macrophages. Immunology (1998) 1.36
Inhibition of interferon-gamma may suppress allograft reactivity by T lymphocytes in vitro and in vivo. Science (1985) 1.30
Distribution of interferon-gamma receptor in human tissues. Eur J Immunol (1992) 1.30
Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst (1997) 1.30
Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today (1994) 1.29
The role of the macrophage as the stimulator cell in contact sensitivity. J Immunol (1977) 1.28
Rapid in vivo assay of mouse natural killer cell activity. J Natl Cancer Inst (1979) 1.26
Reactivity of anti-asialo GM1 serum with tumoricidal and non-tumoricidal mouse macrophages. J Leukoc Biol (1985) 1.23
Steroid sensitivity of thymocyte subpopulations during intrathymic differentiation. Effects of 17 beta-estradiol and dexamethasone on subsets expressing T cell antigen receptor or IL-2 receptor. J Immunol (1989) 1.23
Continuous in vivo activation and transient hyporesponsiveness to TcR/CD3 triggering of human gut lamina propria lymphocytes. Eur J Immunol (1993) 1.22
bcl-2 over-expression enhances NF-kappaB activity and induces mmp-9 transcription in human MCF7(ADR) breast-cancer cells. Int J Cancer (2000) 1.22
Cystine accumulation and clearance by normal and cystinotic leukocytes exposed to cystine dimethyl ester. Proc Natl Acad Sci U S A (1982) 1.21
Cytotoxic effector cells with the characteristics of natural killer cells in the lungs of mice. Int J Cancer (1980) 1.20
Natural cell-mediated cytotoxicity against Trichomonas vaginalis in the mouse. I. Tissue, strain, age distribution, and some characteristics of the effector cells. J Immunol (1980) 1.18
Identification of the CC chemokines TARC and macrophage inflammatory protein-1 beta as novel functional ligands for the CCR8 receptor. Eur J Immunol (1998) 1.18
Loss of pericentromeric DNA methylation pattern in human glioblastoma is associated with altered DNA methyltransferases expression and involves the stem cell compartment. Oncogene (2007) 1.17
In vivo natural reactivity of mice against tumor cells. Int J Cancer (1980) 1.16
Tumor localization in patients by radiolabeled monoclonal antibodies against colon carcinoma. Cancer Res (1983) 1.16
Obligatory role of IFN-gamma in induction of lymphokine-activated and T lymphocyte killer activity, but not in boosting of natural cytotoxicity. J Immunol (1988) 1.15
Familial tumoral calcinosis and testicular microlithiasis associated with a new mutation of GALNT3 in a white family. J Clin Pathol (2006) 1.15
Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol (1992) 1.15
Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically. Br J Cancer (1994) 1.15
Inhibition of tumor growth and enhancement of metastasis after transfection of the gamma-interferon gene. Int J Cancer (1993) 1.15
p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. Int J Cancer (2000) 1.14
Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12. Cancer Res (1999) 1.14
Expression of an exogenous interleukin 6 gene in human Epstein Barr virus B cells confers growth advantage and in vivo tumorigenicity. J Exp Med (1990) 1.14
Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth. J Immunol (1985) 1.11
PI3K/AKT signaling determines a dynamic switch between distinct KSRP functions favoring skeletal myogenesis. Cell Death Differ (2011) 1.11
HTLV-V: a new human retrovirus isolated in a Tac-negative T cell lymphoma/leukemia. Science (1987) 1.10
IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J Immunol (2001) 1.10
Searching for rehabilitation articles on MEDLINE and EMBASE. An example with cross-over design. Arch Phys Med Rehabil (2000) 1.09
Neutrophils in the antitumoral immune response. Chem Immunol Allergy (2003) 1.09
Heterologous sera: a target for in vitro cell-mediated cytotoxicity. J Immunol (1976) 1.09
A comprehensive overview of grain development in Brachypodium distachyon variety Bd21. J Exp Bot (2011) 1.08
IL-6 expression in neurons of transgenic mice causes reactive astrocytosis and increase in ramified microglial cells but no neuronal damage. Eur J Neurosci (1995) 1.08
Cardiac growth factors in human hypertrophy. Relations with myocardial contractility and wall stress. Circ Res (1999) 1.08
Mutant lines of guinea pig L2C leukemia. I. Deletion of Ia alloantigens is associated with a loss in immunogenicity of tumor-associated transplantation antigens. J Exp Med (1976) 1.08
Cutting edge: functional role for proline-rich tyrosine kinase 2 in NK cell-mediated natural cytotoxicity. J Immunol (2000) 1.08
Inactivation of the IL-6 gene prevents development of multicentric Castleman's disease in C/EBP beta-deficient mice. J Exp Med (1996) 1.08
Carbon monoxide pretreatment prevents respiratory derangement and ameliorates hyperacute endotoxic shock in pigs. FASEB J (2005) 1.07
Environmental signals influencing expression of the IFN-gamma receptor on human T cells control whether IFN-gamma promotes proliferation or apoptosis. J Immunol (1994) 1.06
In vivo reactivity of mouse natural killer (NK) cells against normal bone marrow cells. Cell Immunol (1981) 1.06